UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

| --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | Corporate Overview NASDAQ: STTK April 1, 2021 | | | | | | | | | | | | | | | SHATTUCK PIONEERING NOVEL BI-FUNCTIONAL FUSION PROTEINS EXPANDING THE BOUNDARIES OF BIOLOGIC MEDICINES Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substan ...

| --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | Corporate Overview NASDAQ: STTK March 16, 2021 | | | | | | | | | | | SHATT PIONEERING NOVEL BI-FUNCTIONAL FUSION PROTEINS EXPANDING THE BOUNDARIES OF BIOLOGIC MEDICINES Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are base ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...

Company Overview - Shattuck Labs is a clinical-stage biotechnology company pioneering bi-functional fusion proteins for therapeutic immune modulation[9] - The company's initial public offering (IPO) in October 2020 resulted in net proceeds of approximately $213.5 million[10] - Shattuck Labs anticipates its cash runway will extend through 2024, with multiple key clinical data readouts expected[10] Pipeline and Platform Technologies - The company has over 300 unique bi-functional fusion proteins in its ARC and GADLEN platforms[9, 38] - SL-172154, a CD47/SIRPα inhibitor and CD40 agonist, is in Phase 1 trials for ovarian cancer, head & neck cancer, and cutaneous squamous cell carcinoma, with initial dose escalation data expected in 2H'2021 and 1H'2022[9, 17, 124] - SL-279252, a PD-1/PD-L1 inhibitor and OX40 agonist partnered with Takeda, is in Phase 1 trials for advanced solid tumors and lymphoma, with dose escalation data expected in 2H'2021[9, 17, 124] Financial Performance - For the three months ended September 30, 2020, collaboration revenue was $2.4 million, R&D expense was $11.8 million, G&A expense was $2.5 million, and net loss was $11.8 million[119, 120, 121, 122] - For the nine months ended September 30, 2020, collaboration revenue was $8.6 million, R&D expense was $27.7 million, G&A expense was $5.8 million, and net loss was $24.6 million[119, 120, 121, 122] - As of September 30, 2020, Shattuck Labs had $134.9 million in cash, cash equivalents, and short-term investments[122]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...